Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to join others in celebrating the launch of the UK Dementia Research Institute (DRI) this week. The Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK have made this important £250m investment, in response to the Prime Minister’s Challenge on Dementia 2020.

Through the DRI’s ambitious approach to discovery science, and alongside the significant amounts of data provided by DPUK’s commitment to platform science, together we will make significant advances in dementia research, aiming to put the UK firmly on the map as the global lead.

DPUK will bring together carefully collected data on more than 2m people from the wealth of cohorts in the UK. This will help researchers to understand dementias better, and to select participants for trials in a targeted way. Complementing this people data resource, the DRI will focus initially on cellular and animal research. This will boost understanding and interventions for dementias; its researchers will identify new drug targets and drive new approaches to diagnosis, treatment, care and prevention.

Professor John Gallacher, Dementias Platform UK Director, said, “This is an important day for dementias research. The DRI and DPUK will have real impact together, and I hope we will look back on these years as the turning point for reducing – and better treating – the dementias. The impact on people’s lives should be tremendous.”